Mirai Medical Company Market Research Report

Company Overview

• Company Name: Mirai Medical

• Mission: No information is available.

• Founded By: No information is available.

• Key People: No information is available.

• Headquarters: Unit 5, Howley Court, Oranmore, Galway, Ireland.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Mirai Medical is known for developing ePORE® therapy, a precision cancer treatment technology aimed at addressing unmet challenges in gastrointestinal and skin cancer treatments.

Products

ePORE® Therapy

• Description: ePORE® therapy utilizes pulsed electrical fields to increase cell membrane permeability for effective treatment of cancer. It targets tumor tissue while preserving healthy tissue.

• Key Features:

• Precision-based treatment with minimal side effects.

• Cost-effective as it can be performed under local anaesthetic.

• Alternative treatment that can be used in conjunction with chemotherapy and surgery.

• Repeatable to ensure effective tumor removal.

• Can be used endoscopically for gastrointestinal cancers and various skin cancers.

EndoVE®

• Description: An innovative device for the endoscopic delivery of pulsed electrical fields to gastrointestinal tissue. Used in conjunction with a gastroscope or colonoscope.

• Key Features:

• CE approved for safe application.

• Equipped with a vacuum chamber to draw the tumor into contact with electrodes.

• Effective reduction of gastrointestinal tumors in single treatments.

• Minimal hospitalisation and leaves standard treatment options available.

CUTIS

• Description: An electrode designed for the delivery of pulsed electrical fields to cutaneous tumors.

• Key Features:

• Used on non-melanoma skin cancers, metastatic melanoma, and other cutaneous cancers.

• Allows delivery of electrical fields while preserving cosmetic appearance.

• Cost-effective with minimal treatment time required.

Recent Developments

• Recent Developments: No detailed information is available about recent developments apart from existing product approvals.

• New Products Launched: No information is available.

• New Features Added to Existing Products: No information is available.

• New Partnerships: No specific partnerships mentioned, but ePORE® therapy is approved for commercialization in the European Union, the United Kingdom, and Australia.

Regulatory Information

• Commercialization Status: ePORE® therapy, EndoVE®, and CUTIS are approved for commercialization in Europe, UK, and Australia but not by the FDA in the USA.

• Registrations:

• WEEE Ireland Certificate of Registration MIR 100

• PRL Registration Number: IE 02581 WB

Contact Information:

• Email: info@mirai-medical.com

• Social Media: Twitter, LinkedIn, YouTube

Note: Further corporate insights, financial figures, and executive details were not available in the provided data.